ATE326240T2 - Zusammensetzung zur prävention kardiovaskulärer erkrankungen - Google Patents

Zusammensetzung zur prävention kardiovaskulärer erkrankungen Download PDF

Info

Publication number
ATE326240T2
ATE326240T2 AT01919650T AT01919650T ATE326240T2 AT E326240 T2 ATE326240 T2 AT E326240T2 AT 01919650 T AT01919650 T AT 01919650T AT 01919650 T AT01919650 T AT 01919650T AT E326240 T2 ATE326240 T2 AT E326240T2
Authority
AT
Austria
Prior art keywords
prevention
formulation
composition
cardiovascular diseases
cardiovascular disease
Prior art date
Application number
AT01919650T
Other languages
English (en)
Inventor
Nicholas John Wald
Malcolm R Law
Original Assignee
Nicholas John Wald
Malcolm R Law
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE326240(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0008791A external-priority patent/GB2361185A/en
Application filed by Nicholas John Wald, Malcolm R Law filed Critical Nicholas John Wald
Application granted granted Critical
Publication of ATE326240T2 publication Critical patent/ATE326240T2/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01919650T 2000-04-10 2001-04-10 Zusammensetzung zur prävention kardiovaskulärer erkrankungen ATE326240T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0008791A GB2361185A (en) 2000-04-10 2000-04-10 Pharmaceutical formulation for the prevention of cardiovascular disease
GB0100548A GB2361186B (en) 2000-04-10 2001-01-09 Formulation for the prevention of cardiovascular disease

Publications (1)

Publication Number Publication Date
ATE326240T2 true ATE326240T2 (de) 2006-06-15

Family

ID=26244072

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01919650T ATE326240T2 (de) 2000-04-10 2001-04-10 Zusammensetzung zur prävention kardiovaskulärer erkrankungen

Country Status (10)

Country Link
EP (1) EP1272220B2 (de)
AT (1) ATE326240T2 (de)
AU (1) AU4671101A (de)
CA (1) CA2406077C (de)
CY (1) CY1105127T1 (de)
DE (1) DE60119715T3 (de)
DK (1) DK1272220T4 (de)
ES (1) ES2263604T5 (de)
PT (1) PT1272220E (de)
WO (1) WO2001076632A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK2692002A3 (en) 1999-08-30 2002-07-02 Aventis Pharma Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
JP4711600B2 (ja) 2001-01-26 2011-06-29 シェーリング コーポレイション シトステロール血症の処置のための置換アゼチジノン化合物の使用
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
DE10222326A1 (de) * 2002-05-16 2003-12-04 Hexal Ag Stabile pharmazeutische Formulierung für eine Kombination aus einem Statin mit einem ACE-Hemmer
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
AU2004208615C1 (en) 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
EP1648422A4 (de) * 2003-07-28 2007-09-19 Reddys Lab Inc Dr Behandlung und prävention von kardiovaskulären ereignissen
BRPI0616223A2 (pt) 2005-09-15 2011-06-14 Otsuka Pharma Co Ltd combinaÇço de fÁrmacos
US20070185065A1 (en) * 2006-02-03 2007-08-09 Vikramjit Chhokar Combination therapy for coronary artery disease
ES2300188B1 (es) * 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN101590240B (zh) * 2008-05-30 2012-04-25 北京奥萨医药研究中心有限公司 含血管紧张素ⅱ受体拮抗剂、他汀和叶酸的组合物及用途
CN101590239B (zh) * 2008-05-30 2013-03-27 北京奥萨医药研究中心有限公司 含有利尿剂、他汀和叶酸的药物组合物及其用途
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (de) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
US9789187B2 (en) 2009-02-11 2017-10-17 Cadila Pharmaceuticals Limited Stable pharmaceutical composition for atherosclerosis
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
PT3573620T (pt) 2017-01-25 2023-03-20 The George Inst For Global Health Composições para o tratamento da hipertensão
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948443A (en) † 1996-02-23 1999-09-07 Medical Doctor's Research Institute, Inc. Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease
CA2251972A1 (en) * 1996-04-17 1997-10-23 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
WO1998011896A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6054128A (en) † 1997-09-29 2000-04-25 Wakat; Diane Dietary supplements for the cardiovascular system

Also Published As

Publication number Publication date
CA2406077C (en) 2010-07-20
DE60119715D1 (de) 2006-06-22
DE60119715T3 (de) 2016-12-08
PT1272220E (pt) 2006-10-31
ES2263604T5 (es) 2017-02-07
DE60119715T2 (de) 2007-03-15
DK1272220T4 (en) 2016-11-28
CY1105127T1 (el) 2009-11-04
ES2263604T3 (es) 2006-12-16
AU4671101A (en) 2001-10-23
EP1272220A1 (de) 2003-01-08
EP1272220B1 (de) 2006-05-17
DK1272220T3 (da) 2006-09-25
CA2406077A1 (en) 2001-10-18
WO2001076632A1 (en) 2001-10-18
EP1272220B2 (de) 2016-07-27

Similar Documents

Publication Publication Date Title
DE60119715D1 (de) Zusammensetzung zur prävention kardiovaskulärer erkrankungen
EP0693281A3 (de) Pharmazeutische Zubereitungen, die Fluoxetin enthalten
EP1478322A4 (de) Beta-2'-OR 3'-HALONUCLEOSIDE
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
NO20053143L (no) Farmasoytiske sammensetninger omfattende en basisk, henholdsvis sur legemiddelforbindelse, en sufaktant og en fysiologisk akseptabel vannloselig syre henholdsvis base.
MY136707A (en) Thrombopoietin mimetics
BG66080B1 (bg) Заместени тиоацетамиди
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
MXPA02012937A (es) Combinaciones de productos activos con propiedades insecticidas y acaricidas.
CA2420874A1 (en) Active ingredient combinations with insecticidal and acaricidal properties
WO2005018605A3 (en) Novel formulation of ropinirole
ATE396697T1 (de) Zuckerlacton enthaltende zusammensetzung zur haarbehandlung
ATE422892T1 (de) Verwendung von hyaluronsäure zur herstellung von zusammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle
WO2002089749A3 (en) Arylsulfonamide ethers, and methods of use thereof
DE60213283D1 (de) Pharmazeutische zusammensetzung enthaltend magermilchpulver
PL1682162T3 (pl) Zastosowanie opuncji do leczenia depresyjnych rozstrojów i chorób
EA200400751A1 (ru) Применение дезоксипеганина для лечения клинической депрессии
ATE481971T1 (de) Formulierung von 3-amino-8-(1-piperazinyl)-2h- 1benzopyran-2-on mit verzögerter freisetzung
JP2002325828A5 (de)
DE60122764D1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
AU2001274138A1 (en) Propanolaminotetralines, preparation thereof and compositions containing same
ATE384521T1 (de) Medikament zur behandlung von durch parasitären protozoen verursachte erkrankungen
DE60305018D1 (de) Citalopram zur behandlung von bluthochdruck
UA47053A (uk) Засіб "евколек" для лікування інфекційно-запальних захворювань жіночих статевих органів
UA40222A (uk) Магносгель для лікування гіперінтоксикації у дітей та дорослих та спосіб його одержання

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272220

Country of ref document: EP